About Biologics

Biologics

Biologic medicines are developed using a complex process, as they are made by or extracted from living organisms, tissues, or cells.¹  These medicines have revolutionized the treatment and prevention of many, disabling and life-threatening diseases in areas such as endocrinology, oncology, immunology, ophthalmology and dermatology.¹

However, as developing and supplying these medicine is  complex, biologics are driving the rising cost of healthcare, and this may restrict patient access to potentially life-saving treatments.² 

The prospect of more affordable options that are as safe and efficacious as the references medicines, opens up opportunities for healthcare systems to expand access to biologics for more patients, free up resources for investment in new areas, and relieve pressured healthcare budgets.

Biosimilars

A biosimilar is a successor to a biologic medicine (also known as ‘reference medicine’) for which the patent has expired and exclusivity has been lost^3,4..

To be approved for use, a biosimilar has to match the reference medicine in terms of quality, safety and efficacy, demonstrating no clinically meaningful differences. This is based on the “totality of evidence” concept using advanced analytical and clinical studies.^5,6  Find out more about the Development of Biosimilars here.

Depending on policies and systems implemented by countries’ healthcare authorities, biosimilars have the potential to improve access challenges faced by patients, generate cost savings for healthcare systems and increase treatment options for healthcare professionals.